<!DOCTYPE html>
<html data-color-mode="light" data-dark-theme="dark_colorblind" data-light-theme="light" lang="zh-CN">
<head>
    <meta content="text/html; charset=utf-8" http-equiv="content-type" />
    <meta name="viewport" content="width=device-width,initial-scale=1.0">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <link href="//cdn.staticfile.net/Primer/21.0.7/primer.css" rel="stylesheet" />
    <link rel="icon" href="https://avatars.githubusercontent.com/u/152575161?s=200&v=4"><script>
        let theme = localStorage.getItem("meek_theme") || "light";
        document.documentElement.setAttribute("data-color-mode", theme);
    </script>
<meta name="description" content=">近十年，以免疫检查点为靶点的免疫疗法(Immune Checkpoint blockades, ICBs) 在癌症治疗中越来越受到关注，但其泛瘤种有效率仅20%左右，如何有效筛选潜在获益人群是肿瘤免疫研究和临床诊治的热点和难点。">
<meta property="og:title" content="TCCIA成果发布与成员招募">
<meta property="og:description" content=">近十年，以免疫检查点为靶点的免疫疗法(Immune Checkpoint blockades, ICBs) 在癌症治疗中越来越受到关注，但其泛瘤种有效率仅20%左右，如何有效筛选潜在获益人群是肿瘤免疫研究和临床诊治的热点和难点。">
<meta property="og:type" content="article">
<meta property="og:url" content="https://OncoHarmony-Network.github.io/post/TCCIA-cheng-guo-fa-bu-yu-cheng-yuan-zhao-mu.html">
<meta property="og:image" content="https://avatars.githubusercontent.com/u/152575161?s=200&v=4">
<title>TCCIA成果发布与成员招募</title>


</head>
<style>
body{box-sizing: border-box;min-width: 200px;max-width: 900px;margin: 20px auto;padding: 45px;font-size: 16px;font-family: sans-serif;line-height: 1.25;}
#header{display:flex;padding-bottom:8px;border-bottom: 1px solid var(--borderColor-muted, var(--color-border-muted));margin-bottom: 16px;}
#footer {margin-top:64px; text-align: center;font-size: small;}

</style>

<style>
.postTitle{margin: auto 0;font-size:40px;font-weight:bold;}
.title-right{display:flex;margin:auto 0 0 auto;}
.title-right .circle{padding: 14px 16px;margin-right:8px;}
#postBody{border-bottom: 1px solid var(--color-border-default);padding-bottom:36px;}
#postBody hr{height:2px;}
#cmButton{height:48px;margin-top:48px;}
#comments{margin-top:64px;}
.g-emoji{font-size:24px;}
@media (max-width: 600px) {
    body {padding: 8px;}
    .postTitle{font-size:24px;}
}
</style>




<body>
    <div id="header">
<h1 class="postTitle">TCCIA成果发布与成员招募</h1>
<div class="title-right">
    <a href="https://OncoHarmony-Network.github.io" id="buttonHome" class="btn btn-invisible circle" title="首页">
        <svg class="octicon" width="16" height="16">
            <path id="pathHome" fill-rule="evenodd"></path>
        </svg>
    </a>
    
    <a href="https://github.com/OncoHarmony-Network/OncoHarmony-Network.github.io/issues/17" target="_blank" class="btn btn-invisible circle" title="Issue">
        <svg class="octicon" width="16" height="16">
            <path id="pathIssue" fill-rule="evenodd"></path>
        </svg>
    </a>
    

    <a class="btn btn-invisible circle" onclick="modeSwitch();" title="切换主题">
        <svg class="octicon" width="16" height="16" >
            <path id="themeSwitch" fill-rule="evenodd"></path>
        </svg>
    </a>

</div>
</div>
    <div id="content">
<div class="markdown-body" id="postBody"><blockquote>
<p>近十年，以免疫检查点为靶点的免疫疗法(Immune Checkpoint blockades, ICBs) 在癌症治疗中越来越受到关注，但其泛瘤种有效率仅20%左右，如何有效筛选潜在获益人群是肿瘤免疫研究和临床诊治的热点和难点。研究表明，环状RNA（circRNA）是肿瘤免疫的关键调控因子，在黑色素瘤等瘤种中展现出作为免疫治疗分子标志物的潜能。然而，人们对circRNA在肿瘤免疫治疗中的作用尚未完全了解。现有的数据资源库要么倾向于疾病和多物种circRNA图谱的解析，要么倾向于肿瘤免疫治疗队列的基因表达研究，还没有能够探索circRNA与肿瘤免疫治疗响应与预后关联的高质量数据研究平台。</p>
</blockquote>
<p><a target="_blank" rel="noopener noreferrer nofollow" href="https://camo.githubusercontent.com/36d214b22feef92d1986300da656c0710ba04ea0e29da76f62767c9dbe4a382c/68747470733a2f2f66696c65732e6d646e6963652e636f6d2f757365722f343333312f38366336303565392d353239322d346165302d626166362d6561633032363232316635322e706e67"><img src="https://camo.githubusercontent.com/36d214b22feef92d1986300da656c0710ba04ea0e29da76f62767c9dbe4a382c/68747470733a2f2f66696c65732e6d646e6963652e636f6d2f757365722f343333312f38366336303565392d353239322d346165302d626166362d6561633032363232316635322e706e67" alt="" data-canonical-src="https://files.mdnice.com/user/4331/86c605e9-5292-4ae0-baf6-eac026221f52.png" style="max-width: 100%;"></a></p>
<blockquote>
<p>基于此，我们在国际著名肿瘤免疫学期刊 <em>Journal for Immunotherapy of Cancer（JITC）</em> （IF2022:10.09，癌症免疫治疗学会会刊，中科院1区，TOP 期刊）上发表题为“TCCIA: A Comprehensive Resource for Exploring CircRNA in Cancer Immunotherapy“的研究成果。研究团队搜集并整合了25个肿瘤免疫治疗临床队列的超过4000例肿瘤样本，然后进行统一的RNA-seq测序原始数据和临床表型数据预处理、circRNA检测、免疫细胞组分解析、肿瘤分子特征评分等，以此构建出首个综合性的肿瘤免疫治疗circRNA数据库TCCIA（The Cancer CircRNA Immunome Atlas），为探索circRNA与肿瘤免疫治疗疗效和肿瘤/免疫分子特征的关联和互作、挖掘和验证circRNA分子标志物提供了重要的数据资源和分析平台。</p>
</blockquote>
<p><a target="_blank" rel="noopener noreferrer nofollow" href="https://camo.githubusercontent.com/73328ec8d1b42eee5a543b8ab23b202f62eee46ec4dc63bf82b95718cd9b8165/68747470733a2f2f66696c65732e6d646e6963652e636f6d2f757365722f343333312f38663631333434662d383931322d346265302d626132322d6462313132623436373963382e706e67"><img src="https://camo.githubusercontent.com/73328ec8d1b42eee5a543b8ab23b202f62eee46ec4dc63bf82b95718cd9b8165/68747470733a2f2f66696c65732e6d646e6963652e636f6d2f757365722f343333312f38663631333434662d383931322d346265302d626132322d6462313132623436373963382e706e67" alt="TCCIA图形摘要" data-canonical-src="https://files.mdnice.com/user/4331/8f61344f-8912-4be0-ba22-db112b4679c8.png" style="max-width: 100%;"></a></p>
<blockquote>
<p>遵义医科大学第二附属医院客座研究员、中山大学肿瘤防治中心博士后王诗翔为本论文第一作者，中南大学湘雅医院博士生熊逸与张益浩为共同第一作者，胸部肿瘤科周建国副主任医师（遵义医科大学未来“科技菁英”计划入选者）、马虎副院长、中山大学肿瘤防治中心赵齐副研究员以及中南大学湘雅医学院李学军副院长为通讯作者。美国国立癌症研究所王海涛研究员、德国纽伦堡-埃尔朗根大学Udo Gaipl教授、南方医科大学珠江医院罗鹏老师、上海交通大学瑞金医院助理研究员李剑峰等对本项目研究提供了指导和支持。该项研究得到了国家自然科学基金、博士后面上基金、贵州省科技厅、教育厅及卫健委、遵义市及学校等相关项目的资助。</p>
</blockquote>
<p>TCCIA数据库链接： <a href="https://shiny.hiplot.cn/TCCIA/" rel="nofollow">https://shiny.hiplot.cn/TCCIA/</a></p>
<p>备选网址：</p>
<ul>
<li><a href="http://tccia.zmu-zhoulab.com/" rel="nofollow">http://tccia.zmu-zhoulab.com/</a></li>
<li><a href="http://shiny.zhoulab.ac.cn/TCCIA" rel="nofollow">http://shiny.zhoulab.ac.cn/TCCIA</a></li>
</ul>
<p>论文链接：<a href="https://jitc.bmj.com/content/12/1/e008040" rel="nofollow">https://jitc.bmj.com/content/12/1/e008040</a></p>
<h2>我们在招募</h2>
<h3>我们是谁</h3>
<blockquote>
<p>我们是由王诗翔和周建国博士创建的在线协作科研团队 <a href="https://github.com/OncoHarmony-Network" title="OncoHarmony Network">OncoHarmony Network</a>，致力于肿瘤免疫方向的资源平台构建和数据挖掘。我们通过项目导向、贡献优先、成果共享的协作原则一起工作。今天推送的文章就是我们的第一个协作成果，后续我们有更多的项目计划需要有能力、负责任的同行朋友参与。</p>
<p>OncoHarmony Network is a dynamic collaborative platform dedicated to advancing the frontier of cancer immunotherapy. Bringing together diverse teams from leading universities and research institutions, our network is committed to the exploration, mining, and integration of multi-omics data in the realm of cancer research. With a focus on fostering synergy among experts in the field, OncoHarmony Network aims to construct a comprehensive resource hub and cutting-edge tools for unraveling the complexities of tumor-immune interactions. Through collective knowledge and interdisciplinary collaboration, we strive to accelerate breakthroughs in the understanding and development of effective cancer therapies.</p>
<p>团队结构：<a href="https://zhoulab.ac.cn/post/tuan-dui-jia-gou.html" rel="nofollow">https://zhoulab.ac.cn/post/tuan-dui-jia-gou.html</a></p>
</blockquote>
<h3>需要这样的你</h3>
<blockquote>
<p>我们以未来成果第一作者的标准招募有志之士：</p>
<ul>
<li>团队相关领域的研究生、博士：有稳定可控的参与和贡献时间，自律、自主、自驱动、能协作、好沟通。</li>
<li><strong>良好的 Git(Hub) Profile</strong>：掌握 Shiny 或专业 Web 开发或生信技能（流程搭建、数据分析与可视化）。</li>
</ul>
</blockquote>
<h3>联系方式</h3>
<blockquote>
<p>如果读者有意，请将以下信息发送给王诗翔（<a href="mailto:w_shixiang@163.com">w_shixiang@163.com</a>）博士：</p>
<ul>
<li>GitHub（或其他Git平台）个人主页</li>
<li>个人简历（或谷歌学术、ResearchGate等主页）</li>
<li>自我评价</li>
</ul>
</blockquote>
<p>招募常年有效。</p></div>
<div style="font-size:small;margin-top:8px;float:right;"></div>
<button class="btn btn-block" type="button" onclick="openComments()" id="cmButton">评论</button>
<div class="comments" id="comments"></div>
</div>
    <div id="footer">Copyright © <span id="year"></span><a href="https://OncoHarmony-Network.github.io"> OncoHarmony Network </a>
<p>
<span id="runday"></span>Powered by <a href="https://meekdai.com/Gmeek.html" target="_blank">Gmeek</a>
</p>

<script>
if("12/01/2023"!=""){
    var now=new Date();
    var startSite=new Date("12/01/2023");
    var diff=now.getTime()-startSite.getTime();
    var diffDay=Math.floor(diff/(1000*60*60*24));
    document.getElementById("year").innerHTML=now.getFullYear();
    if(""!=""){document.getElementById("runday").innerHTML=" • "+"网站运行"+diffDay+"天"+" • ";}
    else{document.getElementById("runday").innerHTML="网站运行"+diffDay+"天"+" • ";}
}
</script>
</div>
</body>
<script>
var IconList={'sun': 'M8 10.5a2.5 2.5 0 100-5 2.5 2.5 0 000 5zM8 12a4 4 0 100-8 4 4 0 000 8zM8 0a.75.75 0 01.75.75v1.5a.75.75 0 01-1.5 0V.75A.75.75 0 018 0zm0 13a.75.75 0 01.75.75v1.5a.75.75 0 01-1.5 0v-1.5A.75.75 0 018 13zM2.343 2.343a.75.75 0 011.061 0l1.06 1.061a.75.75 0 01-1.06 1.06l-1.06-1.06a.75.75 0 010-1.06zm9.193 9.193a.75.75 0 011.06 0l1.061 1.06a.75.75 0 01-1.06 1.061l-1.061-1.06a.75.75 0 010-1.061zM16 8a.75.75 0 01-.75.75h-1.5a.75.75 0 010-1.5h1.5A.75.75 0 0116 8zM3 8a.75.75 0 01-.75.75H.75a.75.75 0 010-1.5h1.5A.75.75 0 013 8zm10.657-5.657a.75.75 0 010 1.061l-1.061 1.06a.75.75 0 11-1.06-1.06l1.06-1.06a.75.75 0 011.06 0zm-9.193 9.193a.75.75 0 010 1.06l-1.06 1.061a.75.75 0 11-1.061-1.06l1.06-1.061a.75.75 0 011.061 0z', 'moon': 'M9.598 1.591a.75.75 0 01.785-.175 7 7 0 11-8.967 8.967.75.75 0 01.961-.96 5.5 5.5 0 007.046-7.046.75.75 0 01.175-.786zm1.616 1.945a7 7 0 01-7.678 7.678 5.5 5.5 0 107.678-7.678z', 'sync': 'M1.705 8.005a.75.75 0 0 1 .834.656 5.5 5.5 0 0 0 9.592 2.97l-1.204-1.204a.25.25 0 0 1 .177-.427h3.646a.25.25 0 0 1 .25.25v3.646a.25.25 0 0 1-.427.177l-1.38-1.38A7.002 7.002 0 0 1 1.05 8.84a.75.75 0 0 1 .656-.834ZM8 2.5a5.487 5.487 0 0 0-4.131 1.869l1.204 1.204A.25.25 0 0 1 4.896 6H1.25A.25.25 0 0 1 1 5.75V2.104a.25.25 0 0 1 .427-.177l1.38 1.38A7.002 7.002 0 0 1 14.95 7.16a.75.75 0 0 1-1.49.178A5.5 5.5 0 0 0 8 2.5Z', 'home': 'M6.906.664a1.749 1.749 0 0 1 2.187 0l5.25 4.2c.415.332.657.835.657 1.367v7.019A1.75 1.75 0 0 1 13.25 15h-3.5a.75.75 0 0 1-.75-.75V9H7v5.25a.75.75 0 0 1-.75.75h-3.5A1.75 1.75 0 0 1 1 13.25V6.23c0-.531.242-1.034.657-1.366l5.25-4.2Zm1.25 1.171a.25.25 0 0 0-.312 0l-5.25 4.2a.25.25 0 0 0-.094.196v7.019c0 .138.112.25.25.25H5.5V8.25a.75.75 0 0 1 .75-.75h3.5a.75.75 0 0 1 .75.75v5.25h2.75a.25.25 0 0 0 .25-.25V6.23a.25.25 0 0 0-.094-.195Z', 'github': 'M8 0c4.42 0 8 3.58 8 8a8.013 8.013 0 0 1-5.45 7.59c-.4.08-.55-.17-.55-.38 0-.27.01-1.13.01-2.2 0-.75-.25-1.23-.54-1.48 1.78-.2 3.65-.88 3.65-3.95 0-.88-.31-1.59-.82-2.15.08-.2.36-1.02-.08-2.12 0 0-.67-.22-2.2.82-.64-.18-1.32-.27-2-.27-.68 0-1.36.09-2 .27-1.53-1.03-2.2-.82-2.2-.82-.44 1.1-.16 1.92-.08 2.12-.51.56-.82 1.28-.82 2.15 0 3.06 1.86 3.75 3.64 3.95-.23.2-.44.55-.51 1.07-.46.21-1.61.55-2.33-.66-.15-.24-.6-.83-1.23-.82-.67.01-.27.38.01.53.34.19.73.9.82 1.13.16.45.68 1.31 2.69.94 0 .67.01 1.3.01 1.49 0 .21-.15.45-.55.38A7.995 7.995 0 0 1 0 8c0-4.42 3.58-8 8-8Z'};
var utterancesLoad=0;

let themeSettings={
    "dark": ["dark","moon","#00f0ff","dark-blue"],
    "light": ["light","sun","#ff5000","github-light"],
    "auto": ["auto","sync","","preferred-color-scheme"]
};
function changeTheme(mode, icon, color, utheme){
    document.documentElement.setAttribute("data-color-mode",mode);
    document.getElementById("themeSwitch").setAttribute("d",value=IconList[icon]);
    document.getElementById("themeSwitch").parentNode.style.color=color;
    if(utterancesLoad==1){utterancesTheme(utheme);}
}
function modeSwitch(){
    let currentMode=document.documentElement.getAttribute('data-color-mode');
    let newMode = currentMode === "light" ? "dark" : currentMode === "dark" ? "auto" : "light";
    localStorage.setItem("meek_theme", newMode);
    if(themeSettings[newMode]){
        changeTheme(...themeSettings[newMode]);
    }
}
function utterancesTheme(theme){
    const message={type:'set-theme',theme: theme};
    const iframe=document.getElementsByClassName('utterances-frame')[0];
    iframe.contentWindow.postMessage(message,'https://utteranc.es');
}
if(themeSettings[theme]){changeTheme(...themeSettings[theme]);}
console.log("\n %c Gmeek main https://github.com/Meekdai/Gmeek \n\n","padding:5px 0;background:#02d81d;color:#fff");
</script>

<script>
document.getElementById("pathHome").setAttribute("d",IconList["home"]);
document.getElementById("pathIssue").setAttribute("d",IconList["github"]);

function openComments(){
    cm=document.getElementById("comments");
    cmButton=document.getElementById("cmButton");
    cmButton.innerHTML="loading";
    span=document.createElement("span");
    span.setAttribute("class","AnimatedEllipsis");
    cmButton.appendChild(span);

    script=document.createElement("script");
    script.setAttribute("src","https://utteranc.es/client.js");
    script.setAttribute("repo","OncoHarmony-Network/OncoHarmony-Network.github.io");
    script.setAttribute("issue-term","title");
    
    if(localStorage.getItem("meek_theme")=="dark"){script.setAttribute("theme","dark-blue");}
    else if(localStorage.getItem("meek_theme")=="light") {script.setAttribute("theme","github-light");}
    else{script.setAttribute("theme","preferred-color-scheme");}
    
    script.setAttribute("crossorigin","anonymous");
    script.setAttribute("async","");
    cm.appendChild(script);

    int=self.setInterval("iFrameLoading()",200);
}

function iFrameLoading(){
    var utterances=document.getElementsByClassName('utterances');
    if(utterances.length==1){
        if(utterances[0].style.height!=""){
            utterancesLoad=1;
            int=window.clearInterval(int);
            document.getElementById("cmButton").style.display="none";
            console.log("utterances Load OK");
        }
    }
}
</script>



</html>
